The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies. McKay FC, Gatt PN, Fewings N, Parnell GP, Schibeci SD, Basuki MAI, Powell J, Fabis-Pedrini MJ, Kermode AG, Burke T, Vucic S, Stewart GJ, Booth DR. Clin Immunol. 2016 Feb;163:96-107. doi: 10.1016/j.clim.2015.12.015